-
IRVINE, California Inefficiencies, inequities, escalating costs and issues of access within the U.S. healthcare system have continued to challenge both the public and private sectors for well over a decade.
-
PHOENIX, Arizona Ischemic stroke accounts for 80% to 85% of the estimated 750,000 strokes that occur annually in the U.S. Thus, it was no surprise that at this years International Stroke Conference, sponsored annually by the American Heart Association (Dallas, Texas) and held here in February, issues and developments related to ischemic stroke were in the limelight.
-
With the salient risk factor for development of cardiovascular disease being advancing old age, research cardiologist Roger Hajjar notes that efforts to develop gene therapy for heart disease have been geared toward the elderly, since they have fewer therapeutic options.
-
Todd Schermerhorn has been named senior vice president and chief financial officer of C.R. Bard (Murray Hill, New Jersey), replacing Charles Slacik, who has resigned.
-
-
The explosion of Internet-based advertising for genetic tests has provoked a sharp reaction from the European Unions top advisers on ethics. They issued a call for caution last month and promised to investigate the matter closely.
-
CardioTech International (Woburn, Massachusetts) said it would complete the acquisition of Gish Biomedical (Rancho Santa Margarita, California) by April 7. The value of the stock-for-stock deal has not been disclosed.
-
Abiomed (Danvers, Massachusetts) last month rolled out plans to develop a new line of ventricular-assist devices, suggesting both a return to its initial development effort and an inflection point in its progress with the AbioCor replacement heart program.
-
AST Products (Billerica, Massachusetts), a developer of water-based coatings for medical devices, has completed a licensing agreement with MicroPort Medical (Shanghai, China) for its LubriLAST coating.
-
Women who undergo open-heart surgery are more likely than men to develop acute renal failure (ARF), according to research conducted at The Cleveland Clinic (Cleveland, Ohio).
